About 121 Bio
121 Bio is a Healthcare company based in Boston (United States) founded in 2013, and was acquired by Agenusbio in June 2016. Antibody-based tools for protein modification and immunotherapies are developed. The company was acqui-hired. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is 121 Bio LLC. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2013 and based in Boston, United States, 121 Bio operates in the biopharmaceutical sector. Research tools for protein and cell modification, along with cellular immunotherapies, are developed using proprietary enzymatic conjugation and single-domain antibody technologies. Antibody-based solutions are offered to academic and commercial laboratories through its core platform.
- Headquarters Boston, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website 121bio.com
- Acquired by Agenusbio (Jun 2016)
- Legal Name 121 Bio Llc
Investors in 121 Bio
121 Bio has secured backing from 1 investor. Prominent investors backing the company include Agenusbio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of immunotherapies to treat cancer | 1994 | agenusbio.com | Lexington, United States |
Investor details for 121 Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of 121 Bio
2 dated milestones of 121 Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded 121 Bio is founded.
- Exit Acquired by Agenusbio.
Competitors of 121 Bio
121 Bio has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of 121 Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as 121 Bio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about 121 Bio
121 Bio was founded in 2013.
121 Bio is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Founded in 2013 and based in Boston, United States, 121 Bio operates in the biopharmaceutical sector. Research tools for protein and cell modification, along with cellular immunotherapies, are developed using proprietary enzymatic conjugation and single-domain antibody technologies. Antibody-based solutions are offered to academic and commercial laboratories through its core platform.
121 Bio's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
121 Bio has 1 investor. Key investors include Agenusbio.
121 Bio operates through 121 Bio Llc.
Yes. 121 Bio was acquired by Agenusbio in June 2016.